TW455628B - Contact lenses with aqueous solution including phosphonic compounds and cleaning aqueous solution thereof - Google Patents
Contact lenses with aqueous solution including phosphonic compounds and cleaning aqueous solution thereof Download PDFInfo
- Publication number
- TW455628B TW455628B TW086103303A TW86103303A TW455628B TW 455628 B TW455628 B TW 455628B TW 086103303 A TW086103303 A TW 086103303A TW 86103303 A TW86103303 A TW 86103303A TW 455628 B TW455628 B TW 455628B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- amine
- contact lenses
- substituted
- cleaning
- Prior art date
Links
- 238000004140 cleaning Methods 0.000 title claims abstract description 50
- 150000001875 compounds Chemical class 0.000 title claims abstract description 36
- 239000007864 aqueous solution Substances 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 67
- -1 phosphonic acid compound Chemical class 0.000 claims abstract description 45
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 33
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 20
- 230000001590 oxidative effect Effects 0.000 claims abstract description 17
- 239000004599 antimicrobial Substances 0.000 claims abstract description 13
- 230000002265 prevention Effects 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 114
- 150000003839 salts Chemical class 0.000 claims description 34
- 150000001412 amines Chemical class 0.000 claims description 33
- 125000004432 carbon atom Chemical group C* 0.000 claims description 33
- 102000004190 Enzymes Human genes 0.000 claims description 27
- 108090000790 Enzymes Proteins 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 25
- 238000011049 filling Methods 0.000 claims description 23
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
- 125000002947 alkylene group Chemical group 0.000 claims description 19
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000012459 cleaning agent Substances 0.000 claims description 12
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 11
- 125000003277 amino group Chemical group 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 239000004094 surface-active agent Substances 0.000 claims description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 10
- 229940123208 Biguanide Drugs 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000002079 cooperative effect Effects 0.000 claims description 9
- 230000000249 desinfective effect Effects 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- 230000003204 osmotic effect Effects 0.000 claims description 8
- 229920000642 polymer Polymers 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000005647 linker group Chemical group 0.000 claims description 7
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 claims description 7
- 150000003512 tertiary amines Chemical class 0.000 claims description 7
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 230000008901 benefit Effects 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 239000007789 gas Substances 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 3
- 230000000845 anti-microbial effect Effects 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 239000000417 fungicide Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 238000005201 scrubbing Methods 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 239000013589 supplement Substances 0.000 claims description 3
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 125000005263 alkylenediamine group Chemical group 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 238000007654 immersion Methods 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 241000024244 Chelis Species 0.000 claims 1
- 229910018828 PO3H2 Inorganic materials 0.000 claims 1
- 241000277331 Salmonidae Species 0.000 claims 1
- 241000242583 Scyphozoa Species 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical group 0.000 claims 1
- 230000003139 buffering effect Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 230000003641 microbiacidal effect Effects 0.000 claims 1
- 229940124561 microbicide Drugs 0.000 claims 1
- 239000002855 microbicide agent Substances 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 30
- 235000002639 sodium chloride Nutrition 0.000 description 26
- 229940088598 enzyme Drugs 0.000 description 22
- 230000008859 change Effects 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000017 hydrogel Substances 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 150000003009 phosphonic acids Chemical class 0.000 description 6
- 239000012085 test solution Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000006196 drop Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- QQVDJLLNRSOCEL-UHFFFAOYSA-N (2-aminoethyl)phosphonic acid Chemical compound [NH3+]CCP(O)([O-])=O QQVDJLLNRSOCEL-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 4
- 239000004327 boric acid Substances 0.000 description 4
- 239000006172 buffering agent Substances 0.000 description 4
- 239000000882 contact lens solution Substances 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 4
- 150000002978 peroxides Chemical class 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000002280 amphoteric surfactant Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000003899 bactericide agent Substances 0.000 description 3
- 150000004283 biguanides Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910021538 borax Inorganic materials 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000008151 electrolyte solution Substances 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000003352 sequestering agent Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000010339 sodium tetraborate Nutrition 0.000 description 3
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- VPTUPAVOBUEXMZ-UHFFFAOYSA-N (1-hydroxy-2-phosphonoethyl)phosphonic acid Chemical compound OP(=O)(O)C(O)CP(O)(O)=O VPTUPAVOBUEXMZ-UHFFFAOYSA-N 0.000 description 2
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 2
- RXGSAYBOEDPICZ-UHFFFAOYSA-N 2-[6-[[amino-(diaminomethylideneamino)methylidene]amino]hexyl]-1-(diaminomethylidene)guanidine Chemical compound NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)N RXGSAYBOEDPICZ-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920001090 Polyaminopropyl biguanide Polymers 0.000 description 2
- 229920000289 Polyquaternium Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229920002359 Tetronic® Polymers 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000008406 cosmetic ingredient Substances 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 229950006191 gluconic acid Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 239000011733 molybdenum Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229940093424 polyaminopropyl biguanide Drugs 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 2
- 229910001948 sodium oxide Inorganic materials 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- XPSXBEJFSQZTBS-UHFFFAOYSA-N 2,2-bis(2-methylprop-2-enoyloxymethyl)butyl 2-methylprop-2-enoate 2-hydroxyethyl 2-methylprop-2-enoate N-(2-methyl-4-oxopentan-2-yl)prop-2-enamide Chemical compound CC(=C)C(=O)OCCO.CC(=O)CC(C)(C)NC(=O)C=C.CCC(COC(=O)C(C)=C)(COC(=O)C(C)=C)COC(=O)C(C)=C XPSXBEJFSQZTBS-UHFFFAOYSA-N 0.000 description 1
- QRIMLDXJAPZHJE-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)CO QRIMLDXJAPZHJE-UHFFFAOYSA-N 0.000 description 1
- CFGGNXFNDNQZKD-UHFFFAOYSA-N 2-(9H-fluoren-1-yl)prop-2-enoic acid Chemical compound C1C2=CC=CC=C2C2=C1C(C(=C)C(=O)O)=CC=C2 CFGGNXFNDNQZKD-UHFFFAOYSA-N 0.000 description 1
- FPWSFGKGWVUHTF-UHFFFAOYSA-N 2-hydroxyethyl 2-methylbut-2-enoate Chemical compound CC=C(C)C(=O)OCCO FPWSFGKGWVUHTF-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- GDTSJMKGXGJFGQ-UHFFFAOYSA-N 3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound O1B([O-])OB2OB([O-])OB1O2 GDTSJMKGXGJFGQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- KNHYFBCCUHCLGL-UHFFFAOYSA-N 3-ethenyl-1h-pyridin-2-one Chemical compound OC1=NC=CC=C1C=C KNHYFBCCUHCLGL-UHFFFAOYSA-N 0.000 description 1
- XZVHBJHXLYHSNN-UHFFFAOYSA-N 4-benzylmorpholin-4-ium-3-carboxylate Chemical compound OC(=O)C1COCCN1CC1=CC=CC=C1 XZVHBJHXLYHSNN-UHFFFAOYSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- UYRFPODVSLYSCO-UHFFFAOYSA-N 4-phosphonobutanoic acid Chemical compound OC(=O)CCCP(O)(O)=O UYRFPODVSLYSCO-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 description 1
- 229950010221 alexidine Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000002009 alkene group Chemical group 0.000 description 1
- 125000005157 alkyl carboxy group Chemical group 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- UXXGWUQNRMPNKH-UHFFFAOYSA-N azane;sulfane Chemical compound N.N.S UXXGWUQNRMPNKH-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000003618 borate buffered saline Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- QVYARBLCAHCSFJ-UHFFFAOYSA-N butane-1,1-diamine Chemical compound CCCC(N)N QVYARBLCAHCSFJ-UHFFFAOYSA-N 0.000 description 1
- RVPHBKHKFNGAOI-UHFFFAOYSA-L calcium;carbonate;dihydrate Chemical compound O.O.[Ca+2].[O-]C([O-])=O RVPHBKHKFNGAOI-UHFFFAOYSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 238000003977 dairy farming Methods 0.000 description 1
- DZQISOJKASMITI-UHFFFAOYSA-N decyl-dioxido-oxo-$l^{5}-phosphane;hydron Chemical compound CCCCCCCCCCP(O)(O)=O DZQISOJKASMITI-UHFFFAOYSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- DUYCTCQXNHFCSJ-UHFFFAOYSA-N dtpmp Chemical compound OP(=O)(O)CN(CP(O)(O)=O)CCN(CP(O)(=O)O)CCN(CP(O)(O)=O)CP(O)(O)=O DUYCTCQXNHFCSJ-UHFFFAOYSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- DKPHLYCEFBDQKM-UHFFFAOYSA-H hexapotassium;1-phosphonato-n,n-bis(phosphonatomethyl)methanamine Chemical compound [K+].[K+].[K+].[K+].[K+].[K+].[O-]P([O-])(=O)CN(CP([O-])([O-])=O)CP([O-])([O-])=O DKPHLYCEFBDQKM-UHFFFAOYSA-H 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- HLERILKGMXJNBU-UHFFFAOYSA-N norvaline betaine Chemical compound CCCC(C([O-])=O)[N+](C)(C)C HLERILKGMXJNBU-UHFFFAOYSA-N 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- DCNLOVYDMCVNRZ-UHFFFAOYSA-N phenylmercury(.) Chemical class [Hg]C1=CC=CC=C1 DCNLOVYDMCVNRZ-UHFFFAOYSA-N 0.000 description 1
- PXBGQFYGVFUKNE-UHFFFAOYSA-N phosphanium;acetate Chemical compound [PH4+].CC([O-])=O PXBGQFYGVFUKNE-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000001194 polyoxyethylene (40) stearate Substances 0.000 description 1
- 235000011185 polyoxyethylene (40) stearate Nutrition 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- JVUYWILPYBCNNG-UHFFFAOYSA-N potassium;oxido(oxo)borane Chemical compound [K+].[O-]B=O JVUYWILPYBCNNG-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- OALLZRITWFSDNC-UHFFFAOYSA-N propan-2-ylidenephosphane Chemical compound CC(C)=P OALLZRITWFSDNC-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- YPPQYORGOMWNMX-UHFFFAOYSA-L sodium phosphonate pentahydrate Chemical compound [Na+].[Na+].[O-]P([O-])=O YPPQYORGOMWNMX-UHFFFAOYSA-L 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- NZSVKAITUCOVRM-UHFFFAOYSA-J tetrasodium 1,2-diphosphonatoethanol Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P(=O)([O-])C(O)CP([O-])([O-])=O NZSVKAITUCOVRM-UHFFFAOYSA-J 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- NPZGSDFOXPZGAQ-UHFFFAOYSA-K trisodium;hydroxy(phosphonatomethyl)phosphinate;tetrahydrate Chemical class O.O.O.O.[Na+].[Na+].[Na+].OP([O-])(=O)CP([O-])([O-])=O NPZGSDFOXPZGAQ-UHFFFAOYSA-K 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Landscapes
- Apparatus For Disinfection Or Sterilisation (AREA)
- Eyeglasses (AREA)
- Detergent Compositions (AREA)
Abstract
Description
A7 455628 ___B7 ______ 五、發明説明(1 ) 發明領域 ϋ. I - .— 111 I I H. 1 -1 -HI - i - I X, . - ·ν·口 (請先閲讀背面之注意事項再填寫本頁) 本發明係有關一種處理隱形眼鏡之方法及其组合物。本 發明包含含有某種膦酸化合物之水溶液之用途。本發明之 較佳具體例包含同時清洗並消毒隱形眼鏡之方法及組合 物。 發明背景 通常,隱形眼鏡廣泛分爲三類:(1)由丙烯酸酯類聚合所 得之材料如聚甲基丙烯酸甲酯(PMMA)所形成之硬式隱形眼 鏡,(2)由矽酮丙烯酸酯及氟矽酮甲基丙締酸酯所形成之硬 質透氣性(RGP)隱形眼鏡,及(3)由聚合親水性或疏水性單 體如甲基丙烯酸2 -羥乙酯(HEMA)所製得之凝膠、水凝膠或 軟式隱形眼鏡。硬式丙烯酸型隱形眼鏡之特徵爲低水蒸氣 擴散常數,·對光、氧及水解具抗性且僅吸收少量水液。 經濟部中央標準局員工消費合作社印製 於正常配戴隱形眼鏡過程中,淚膜及由蛋白質類油性脂 肪及相關有機物質所組成之碎屑易沉積並堆集在隱形眼鏡 表面上。許多因素會影響沉積形成,包含容忍性變化、鏡 片材料 '保養方法及環境。通常,高含水之離子性鏡片比 低含水或非離子性鏡片材料更易吸附蛋白質。例行之保養 方法中’需清洗隱形眼鏡以移除該等淚膜沉積及碎片。若 該等沉積未適當地移除,鏡片之溼潤性及光學透明度本質 上會降低,引起配戴者感覺不舒適。 傳統上,隱形眼鏡係以一或兩種清洗劑清洗。界面活性 劑清洗劑(由於其被建議每天使用因此通常稱”日用清洗劑") 可有效移除大部份之碳水化物及脂質物。但其無法有效移 -4 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 4 5 5 6 2 B A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明(2 ) 除蛋白質類物質如溶菌酶。一般,來自植物、動物及微生 物源之解朊酶係被使用以移除更頑固之蛋白質類沉積。該 等"酵素"清洗劑一般被建議每週使用且通常先使酵素片溶 於適當水溶液中而使用。 再者,隱形眼鏡需經消毒以殺死可能存在或生長於鏡片 上之有害微機體。已使用數種消毒隱形眼鏡之方法,如使 隱形眼鏡與含氧化化學品(如過氧化氛)或抗微生物劑之水 溶液在常溫接觸。或者可使鏡片曝露於高溫下一段特定時 間而完成消毒。後者之消毒技術需使用一般之電予消毒設 備。 清洗及消毒隱形眼鏡,尤其是軟式隱形眼鏡之習知方 法,一般包含最初步驟爲包括清洗相,其中鏡片以日用清 洗劑擦洗以移除碎片再於常溫下浸泡於酵素清洗溶液中, 即浸泡至少1 5分鐘,以有效去除蛋白質類沉積。此方法 中’清洗相之後,需隨後消毒該鏡片。 目前已發展出可自隱形眼鏡移除蛋白質類物質且同時消 毒鏡片之方法。例如USP 4,614,549揭示一種在60。(:至1〇〇 C溫度間以溶菌酶之水溶液清洗並消毒隱形眼鏡之單步驟 方法。不幸地,此方法需使用電予消毒設備及高溫。另一 種同時清洗並消毒隱形眼鏡之方法述於USP申請號32,672, 其揭示一種將隱形眼鏡浸泡於含過氧化物及過氧化物活性 酵素乙溶液中之方法。但此方法在隱形眼鏡配戴前需要中 和殘留過氧化物之額外步驟。 在努力提供更便利之方式中,已發展出新的保養方式。 I________ -5- 本紙張尺度適用中SIS家標準(CNS ) A4規格(2!〇><297公瘦} ' ' -- (請先閱讀背面之注意事項再填寫本筲) 裝· 訂 * -- 1 I mi 455628 第S6103303號專利申請案 中文説明書修正頁(87年9月) Α7 Β7- 3A7 455628 ___B7 ______ V. Description of invention (1) Field of invention ϋ. I-.— 111 II H. 1 -1 -HI-i-IX,.-· Ν · (Please read the precautions on the back before filling in this The present invention relates to a method for treating contact lenses and a composition thereof. The present invention includes the use of an aqueous solution containing a certain phosphonic acid compound. Preferred embodiments of the present invention include methods and compositions for cleaning and disinfecting contact lenses simultaneously. BACKGROUND OF THE INVENTION Generally, contact lenses are broadly divided into three categories: (1) hard contact lenses formed from materials such as polymethyl methacrylate (PMMA) polymerized by acrylates, and (2) silicone acrylates and fluorine RGP contact lenses formed by silicone methylacrylate and (3) gels made by polymerizing hydrophilic or hydrophobic monomers such as 2-hydroxyethyl methacrylate (HEMA) Glue, hydrogel or soft contact lenses. Hard acrylic contact lenses are characterized by a low water vapor diffusion constant, are resistant to light, oxygen and hydrolysis and absorb only a small amount of water. Printed by the Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs During the normal wearing of contact lenses, tear film and debris composed of protein-based oily fats and related organic substances are easily deposited and piled on the surface of contact lenses. Many factors can affect the formation of deposits, including tolerance changes, lens material 'care methods, and environment. Generally, ionic lenses with high water content are more likely to adsorb proteins than low-water or non-ionic lens materials. In the routine maintenance method, contact lenses need to be washed to remove these tear film deposits and debris. If these deposits are not removed properly, the wettability and optical transparency of the lens will be substantially reduced, causing the wearer to feel uncomfortable. Traditionally, contact lenses are cleaned with one or two cleaning agents. Surfactant cleaner (commonly called "Daily Cleaner" because it is recommended for daily use) can effectively remove most of the carbohydrates and lipids. But it cannot effectively remove -4-This paper is for China National Standard (CNS) A4 specification (210X297 mm) 4 5 5 6 2 B A7 B7 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention (2) In addition to proteinaceous substances such as lysozyme. Generally, they come from plants, Animal and microbial-derived enzymes are used to remove more stubborn protein deposits. These " enzyme " cleaning agents are generally recommended for use weekly and enzyme tablets are usually first dissolved in a suitable aqueous solution. Furthermore, contact lenses need to be sterilized to kill harmful micro-organisms that may exist or grow on the lenses. Several methods have been used to disinfect contact lenses, such as contact lenses with oxidizing chemicals (such as peroxide atmosphere) or anti- The aqueous solution of the microbial agent is contacted at normal temperature. Or the lens can be exposed to high temperature for a certain period of time to complete the disinfection. The latter disinfection technology requires general electricity to be disinfected. Equipment. The conventional method for cleaning and disinfecting contact lenses, especially soft contact lenses, generally includes an initial step including a cleaning phase, in which the lenses are scrubbed with a daily cleaning agent to remove debris and then immersed in an enzyme cleaning solution at room temperature, That is, soaking for at least 15 minutes to effectively remove protein deposits. In this method, the lens must be subsequently disinfected after the cleaning phase. At present, methods have been developed that can remove proteinaceous materials from contact lenses and disinfect lenses simultaneously. For example, USP 4,614,549 discloses a single-step method for cleaning and disinfecting contact lenses with an aqueous solution of lysozyme at a temperature between 60 ° C and 100 ° C. Unfortunately, this method requires the use of electricity to disinfect equipment and high temperatures. Another method is to simultaneously clean and disinfect The method of contact lenses is described in USP Application No. 32,672, which discloses a method for immersing contact lenses in a solution containing peroxide and a peroxide-active enzyme B. However, this method needs to neutralize residual peroxide before wearing the contact lenses. Extra steps. In an effort to provide more convenient ways, new maintenance methods have been developed. I_____ ___ -5- This paper size applies to the SIS home standard (CNS) A4 specification (2! 〇 > < 297 male thin) ''-(Please read the precautions on the back before filling in this card) -1 I mi 455628 No. S6103303 Patent Application Chinese Specification Revision Sheet (September 87) Α7 Β7- 3
.L -玄*^·會明年明( 例"年3月17日核准之USP 5,096,607揭示一種清洗及 消毒系統,其中在酵素片存在下在某種滲透條件下,將隱 形眼鏡含浸於多目的溶液中而同時清洗並消毒鏡片。此系 統提供一種單一” EJ用"清洗及消毒溶液之利益,其可與酵 素類清洗劑组合而同時使用,因而減少有效清洗及消毒隱 形眼鏡所需之步驟次數。 雖然後一專利在清洗隱形眼鏡方面提供比先前系統更重 要之改良,但仍企求更便利之方法s更特定言之,仍期望 提供僅使用單一溶液而不需補充酵素清洗劑之清洗系統, 該清洗系統可提供與利用酵素清洗劑之系統可相較之清洗 力。 ^ 發明概要 本發明包含處理隱形眼鏡之非氡化方法及其組合物。本 發明包含使隱形眼鏡與含下式之膦酸或其生理可相容鹽之 水溶液接觸:.L-玄 * ^ will be revealed next year (eg, USP 5,096,607, approved on March 17, 2009) reveals a cleaning and disinfection system in which contact lenses are impregnated with a multi-purpose solution in the presence of enzyme tablets under certain osmotic conditions The lens is cleaned and disinfected at the same time. This system provides the benefit of a single "EJ" cleaning and disinfection solution, which can be used in combination with enzyme cleaning agents, thereby reducing the number of steps required to effectively clean and disinfect contact lenses. . Although the latter patent provides more important improvements in cleaning contact lenses than previous systems, it still seeks more convenient methods. More specifically, it is still desirable to provide a cleaning system that uses only a single solution without the need to supplement enzyme cleaning agents. The cleaning system can provide a cleaning power comparable to a system using an enzyme cleaning agent. ^ SUMMARY OF THE INVENTION The present invention includes a non-fluorinated method for treating contact lenses and a composition thereof. The present invention includes contact lenses and phosphine containing the following formula Contact with an aqueous solution of an acid or a physiologically compatible salt thereof:
(請先閲讀背面之注意事項再填寫本頁) 訂 經濟部中央標隼局員工消費合作社印製 ⑴ 其中Z爲價數等於η之連接基,其中η爲1至6,較好Z含 有I至1 2個碳原子。z基可包含如經取代或未取代飽和烴基 或含胺之基=”經取代或未取代,,意指未取代或經函素、羥 基、胺基、羧基、烷羰基、烷氧羰基、或經取代或未取代 -Q - 本纸法尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 4 5 56 2 8 Α7 Β7 經濟部中央樣準局員Η消費合作社印製 五、發明説明(4 足苯基所取代,其中苯基上之取代基可爲自素、羥基、胺 基、羧基、規•羰基或烷基,其中該烷基或烷氧基含有1至4 個碳原子。 本發明方法包括以含至少〇 〇〇3。/。重量容積之標的膦酸, 較好爲0.005至1.0%重量容積之標的化合物,更好爲〇〇1至 0 25%重量容積之該化合物之水溶液清洗隱形眼鏡β 較佳具體例中’標的之膦酸化合物可與抗微生物劑組合 使用以提供同時消毒並清洗隱形眼鏡。本發明又更佳具體 例中,標的之隱形眼鏡保養溶液提供隱形眼鏡完全非氧化 之清洗方法,而不需要任何其他溶液或補充酵素清洗劑。 此清洗方法提供可與其他包含使用酵素清洗劑之清洗方法 可相較之蛋白質移除。因此,本發明可提供比已知清洗及 消毒方法更明顯之優點。 發明詳細説明 本發明可使用於所有隱形眼鏡如傳統之硬式、軟式、硬 質及軟透氣性及矽酮(包含水凝膠及非水凝膠)隱形眼鏡, 但較好使用於軟式隱形眼鏡。此種隱形眼鏡一般係由單體 如甲基丙烯酸羥乙酯、曱基丙烯酸羥乙基甲酯、乙烯基吡 啶烷酮、甲基丙缔酸甘油酯、甲基丙烯酸或酸酯等所製 得。此種隱形眼鏡可吸收充分量之水,其量自約4至8 0重 量0/〇。 如前所述,本發明包含一種包括下列(I)所示之膦酸或其 生理可相容鹽: 本紙張尺度適用中国國家標準(CNS ) A4規格ί 210X297公釐) -----^------¥------,tr------^ (請先閱讀背面之注$項再填寫本買) 丨修正扮 A7 B7- 4 5 56 2 8 303號車利申請案 fr修正頁(87年9月) 五、發明説明 / I! \(Please read the notes on the back before filling in this page) Order printed by the Employees' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs, where Z is the linking group whose price is equal to η, where η is 1 to 6, preferably Z contains I to 1 2 carbon atoms. The z group may include, for example, a substituted or unsubstituted saturated hydrocarbon group or an amine-containing group = "substituted or unsubstituted, meaning unsubstituted or mesogen, hydroxyl, amino, carboxyl, alkylcarbonyl, alkoxycarbonyl, or Substituted or unsubstituted -Q-The size of the paper method is applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm) 4 5 56 2 8 Α7 Β7 Printed by the Central Proof Bureau of the Ministry of Economic Affairs Η Printed by Consumer Cooperatives 5. Substituted by a phenyl group, wherein the substituent on the phenyl group may be an autogen, a hydroxyl group, an amine group, a carboxyl group, a carbonyl group, or an alkyl group, wherein the alkyl or alkoxy group contains 1 to 4 carbon atoms. The method comprises washing with an aqueous solution containing at least 003% by weight of the target phosphonic acid, preferably 0.005 to 1.0% by weight of the target compound, more preferably 0.001 to 025% by weight of the compound in an aqueous solution. In the preferred embodiment of the contact lens β, the 'targeted phosphonic acid compound can be used in combination with an antimicrobial agent to provide simultaneous disinfection and cleaning of the contact lens. In a more preferred embodiment of the present invention, the target contact lens maintenance solution provides completely non-contact contact lenses. Of oxidation Washing method without the need for any other solution or supplemental enzyme cleaning agent. This cleaning method provides protein removal that is comparable to other cleaning methods that include the use of enzyme cleaning agents. Therefore, the present invention can provide more than known cleaning and disinfection The method has more obvious advantages. Detailed description of the invention The invention can be used for all contact lenses such as traditional hard, soft, hard and soft breathable and silicone (including hydrogel and non-hydrogel) contact lenses, but it is better to use In soft contact lenses. Such contact lenses are generally composed of monomers such as hydroxyethyl methacrylate, hydroxyethyl methyl methacrylate, vinyl pyridone, glyceryl methacrylate, methacrylic acid or acid. It is made from esters, etc. This contact lens can absorb a sufficient amount of water from about 4 to 80 weight 0/0. As mentioned above, the present invention includes a phosphonic acid or Its physiologically compatible salts: This paper size applies to Chinese National Standard (CNS) A4 specifications 210X297 mm) ----- ^ ------ ¥ ------, tr ----- -^ (Please read the note $ on the back before filling in this purchase) 丨 repair Play A7 B7- 4 5 56 2 8 303 vehicles benefit fr amended application page (87 September) V. description of the invention / I! \
z— P—OH \ 〇H / / n (I) 其中Z爲價數等於n之連接基,其中n爲1至6,較好爲J 至3,且較好Z含有1至12個碳原子,更好含1至10個碳原 子。2基包括經取代或未取代飽和烴基或含胺之基,該含 胺基爲其中埃原子被至少一個氮原子,較好1至3個氮子所 插入而形成二級或三級胺之飽和烴基a當2;爲包括一或多 個二級或三級胺之含胺基時,Z中碳原子數至少爲n + 1。 烴基"意指由碳與氫原子所構成之分枝、未分枝、非環狀或 環狀部份經取代或未取代”意指未取代或經由素、經 基、胺基、叛基、烷羧基、烷氧羰基、或經取代或未取代 之苯基所取代,其中苯基上之取代基可爲画素、羥基、胺 基、羧基、烷羰基或烷基,其中該烷基或烷氧基含有丨至4 個碳原子。較佳之_素爲氣,較佳之取代基爲胺基、羥基 _及經取代或未取代苯基。 據此,適宜之Z基包含經取代或未取代叉烷基、經取代 或未取代伸烷基,具有至少η + 1個碳原子之胺基三(伸烷 基)、具有至少η+1個碳原子之胺基二(伸烷基),伸烷二胺 四(伸烷基)或二伸烷三胺五(伸烷基),其中括派内之各伸 烷基係連接至膦酸基。較好,所有伸烷基均各含丨至4個碳 原子。 其中Ζ基爲胺基三(伸烷基)之化合物實例包含胺基三(乙 -8- _____________ 本紙張尺度逋用中國國家標羋(CNS) Α4規格(2丨0><297公釐〉 (讀先閔讀背面之注意事項再填寫本頁) -訂 經濟部中央標準局員工消費合作杜印製 455628 A7 B7 經濟部中央標準局貝工消費合作社印製 五、發明说明(6 又膦酸)’胺基三(異丙叉膦酸),胺基二(亞甲基膦酸)單 (異丙叉膦酸)’及胺基單(亞曱基膦酸)二(乙叉基膦酸)。 其中Z基爲經取代或未取代叉烷基之化合物實例包含亞甲 基二鱗酸’乙叉一鱗酸’ 1-#至基丙叉二麟酸。其中Z基爲 伸烷二胺四(伸烷基)或二伸烷三胺五(伸烷基)之化合物實 例包含六亞甲基二胺四(亞甲基膦酸)及二伸乙基三胺五(亞 甲基膦酸)。 本發明化合物可以商業獲得或可依本技藝悉知方法製 備,包含揭示於USP 3,671,644之方法。鹵基取代之膦酸化 合物可使用例如PCI3或PBr2由對應之羥基取代之膦酸化合 物製得,如熟悉本技藝悉知者。 本發明之溶液爲生理可相容者。特定言之,溶液需爲可 供隱形眼鏡使用之"眼科安全"者,意指以此溶液處理之隱 形眼鏡通常對未清洗而直接置於眼睛時爲適宜且安全者, 亦即此溶液對經由此溶液溼潤之隱形眼鏡與眼睛每天接觸 時爲安全且舒適者。眼科安全之溶液爲可與眼睛相容之等 張性及pH ’ JL包括依據ISO標準及US. FDA(食品藥物管理 局)規範爲非胞毒素之物質及量。此溶液需爲無菌,而在產 生釋出前無微生物污染,且需統計學證a月至此種產品必要 之程度。 本發明之水溶液較好包括式(I)範圍内而以下式(ΙΪ)表示 之膦酸或其生理可相容鹽, -9- ---------^---1---—1T (請先閱讀背面之注^^項存填寫本頁) A7 OH ί r——?一OH c II ο (Π) 455628 ________B7 五、發明説明(7 ) X2 (卜b X'~^CH2)a~'C—(CH2) 其中a,b ’ c及d各分別選自〇至4之整數,較好b或1 ; X1爲膦酸基(即P(〇H)2〇) ’羥基(0H),胺基(Nh2)或氫(H); 及X2與X3分別選自_素、羥基、胺基、羧基 '烷羰基、烷 氧羰基或經取代或未取代苯基,.及甲基所組成之組群。苯 基上取代基之實例爲鹵素,羥基,胺基,幾基及/或烷基。 較好前述_娱:基及規氧基含有1至4個碳原子,更好含1個碳_ 原子。如前所述’式(II)中碳原子總數較好爲1至12個,更 好1至1 0個。 使用於本發明溶液中其他較佳類化合物包括在式(η)範園 内而以下式(III)表示之化合物及其生理可相容鹽: 0Η (_2)b H2〇3P—(CH2)a—C—(CH2)c-—P〇3H3 (CH2)d CH3 (HI) ,其中a ’ b,c及d各分別選自0至4之整數〇又式(in)中竣 原子總·數較好爲1至12 ’更好1異10。(換言之,式(I工I) ------------^------:—ir (請先閲讀背面之注意事項再填寫本夷) 經濟部中央標準局員工消費合作社印製 ___ ' -10- 4 5 562 8 A7 B7 五、發明説明(8 ) 中,a + b + c + d之和較好爲1至U,更好爲2至9)。 特佳物種爲式(Π)中a,b,c及d均爲0者,特別是1-輕乙 又基-1,1-二膦酸之四鈉鹽,亦表示爲羥乙二膦酸四鈉鹽’ 購自孟山多公司之DeQuest® 2016二膦酸鈉鹽或膦酸鹽。 有機膦酸及其鹽(合稱爲”膦酸化合物爲本技藝悉知 者°此鹽有時表示爲膦酸鹽。此種膦酸化合物之已知用途 包含抑制蒸煮器中鍋垢形成。其他已知用途包含過氧化氫 之安定化作用。例如Tsao等人之USP4,812,173揭示膦酸化 合物用以使用以消毒隱形眼鏡之過氧化氫安定之用途。此 方法爲需要隨後之中和作用之”氧化型"消毒方法之例子。 氧化型消毒之實例爲利用過氧化物之清毒方法。此參考文 獻並未指出一般之”清洗"亦未指出自隱形眼鏡移除蛋白質 類。此種膦酸化合物之其他已知用途包含於含有酚類或四 級銨殺菌劑之防腐组合物中作爲強效劑之用途。此種組合 物發現可應用於鑽泥组合物、化粒品組合物(如洗牙 '手及 頭髮清潔劑)及重型防腐清潔劑組合物(如用於專業洗衣、 洗衣織物、酪農設備、醫院設備等)。 經濟部中央標準局員工消费合作杜印製 標的水溶液宜包含總溶液之至少0.003%重量容積之標的 膦酸,較好爲0.005至1.0°/。重量容積,更好爲〇.〇1至0.25%重 量容積。 標的水溶液亦可含有多種其他成分,包含(但不限於): 抗微生物劑 '緩衝劑、螯合及/或多價螯合劑、等張調節劑 及界面活性劑。 本溶液包括至少一種界面活性劑。適宜之界面活性劑可 -11- 本紙^尺度適用中國國家標隼(CNS ) A4規格(210X297公趁1 " 經濟部中央樣準局員工消費合作社印製 455628 A7 --------51 五、發明説明(9 ) 组 陰離子性或非離子性,其量(個別量或 舌二)可達總組合物(溶液)之15%重量容積,較好達5% 重量谷積(勢較佳之界面活性劑爲兩性或非離子界面活 則其使用時可賦與清洗及調節性質。界面活性劑需可 溶於隱形眼鏡料溶液但對眼睛組織無刺激性。許多非離 子界面活性劑包括-或多種具有氧伸烷基(-0-R-)重複單 =鏈或聚合成分’其中^2至6個竣原子。較佳之非離 ::面活性劑包括兩種或多種不同類氧伸烷基重複單元之 欣&聚〇物,不同重複單元之比例決定了界面活性劑之 HLB 〇令人滿意之非離子界面活性劑包含脂肪酸之聚乙二 醇酯,如高碳烷類(Cim)之柳子酯、聚山梨糖醇酯、聚 氧乙烯醚或聚氧丙烯醚。較佳類之實例包含聚山梨糖醇酯 2 0(以商品名Tween® 20供應),聚氧乙烯(23)月桂醚(Brije 35),聚氧乙烯(4〇)硬脂酸酯(Myrj®52),聚氧乙烯(25)丙 一醇硬脂酸酯(Atlas® G2612)。已發現一種特別是由具有分 子量自約7,500至27,000之伸乙二胺之聚(氧丙烯)_聚(氧乙 晞)加成物(其中該加成物之至少40重量%爲聚(氧乙烯)所 構成之非離子界面活性劑,以約〇 〇丨至〗5重量%使用時,對 於用以清洗及調節軟式及硬式兩種隱形眼鏡特別有利。 CTFA化粧品成份字典對此類界面活性劑所採用之名稱爲普 羅胺(poloxamine) »此種界面活性劑可以註册商標 "Tetronic”購自密西根萬多特之BASF萬多特公司。適用於 本發明之類似系列之界面活性劑爲普羅馬(pol〇xamer)系 列,其爲以商標"Pluronic"(購自B ASF)供應之聚(氧乙烯)聚 -12- 本紙張尺度適用中g國家標準(CMS ) A4規格(2丨0 X 297公釐) ^----^--------ίΐτ------t - :- (請先閔讀背面之注意事項再填寫本頁) 455628 經濟部中夬標隼局貝工消費合作社印製 A7 _______B7 五、發明説明(1〇 ) (氧丙烯)嵌段聚合物。 適用於本發明之各種其他離子性及兩性及陰離子性界面 活性劑可鑑於前述敘述,而易於自Glen Rock NJ07452之北 美編輯McCutcheon分部MC出版公司出版之” McCutr上…,。 这及由華盛頓d.c·化粒品、梳洗品及香料協 會所出版之CTFA國際化粧品成分手册而碹知杳^ 適用於本發明組合物之兩性界面活性劑包含以商品名 "Miranol"銷售之物質。其他類可用之兩性界面活性劑例如 可可醯胺丙基甜菜鹼,購自多種來源。 前述界面活性劑通常總量係自O.Oi至5 〇%重量容積 (w/v) ’較好〇.d5 0%,且最好〇丨至〗5〇/〇。 本溶液之pH需維持在5.0至8.0之範固,更好自约6〇至 8.0,最好自約6·5至7.8,可添加適宜緩衝劑如蝴酸、爛酸 鈉、檸檬酸鉀、檸檬酸 '竣酸氫鈉、了 RIS及各種混合磷酸 鹽緩衝液(包含Na2HP04,NaH2P04及KH2P〇4之组合)及其混 合物。以硼酸鹽緩衝劑較佳’特別是對增強雙胍之效用而 言。通常緩衝劑之用量自約〇.〇5至2.5重量。/。,更好自〇1至 1.5%。本發明之消毒/保存溶液含有硼酸鹽或混合磷酸鹽缓 衝劑’,其含有一或多種硼酸’硼酸鈉’四硼酸钟,偏硼酸 鉀或其混合物。除了緩衝劑外’於某些例中,可於本溶液 中包含多價螯合劑以包圍金屬離子,否則會與鏡片及/或蛋 白質沉積物反應並集於鏡片上D伸乙二胺四乙酸(EDTA)及 其鹽(二鈉)爲較佳實例,其添加量通常自約〇〇ι至〇 3重量 %。其他適宜之多價螯合劑包含葡糖酸、檸檬酸' 酒石酸 ______^13- 本紙張从制中Sil家縣(CNS ) 44職(210X297公釐) ~~ - (請先閲讀背面之注意事項再填寫本頁) .裝 訂 經濟部中央標準局員工消費合作社中製 A7 B7 五、發明説明…) 及其鹽類,如納鹽。 典型上’本發明用以處理隱形眼鏡之水溶液亦以等張劑 凋整至約正常淚液之滲透壓,其等於0.9%氣化鈉溶液或 2.5 /。甘油落液。此溶液可單獨或組合使用生理食鹽水而實 質上製成等張,否則若簡單地以無菌水摻合,則將便隱形 眼鏡變成低滲壓或高滲壓而喪失其所需之光學參數。相對 地,過量之食鹽液可導致形成高滲壓溶液而引起刺痛及眼 睛刺激。 適苴之張力調節劑之實例包含(但不限於):氣化鈉及氯 化鉀,左旋糖,甘油,氣化鈣及氣化鎂。此等藥劑一般之 個别使用量自約〇_〇1至2.5%(w/v)卫較好自約〇·2至1.5% (w/v)。較好等張劑使用之量爲可提供最終滲透壓値爲2〇〇 至450 mOsm/kg且更好介於約250至350 mOsm/kg之間且最好 介於約280至320 mOsm/kg之間。 耶希望於本發明溶液中包含水可溶黏度構成劑。由於其 緩和效果,黏度構成劑具有增進配戴者舒適之傾向,係藉 鏡片表面上之膜緩衝衝擊眼睛。此種水可溶液度構成劑包 含纖维素聚合物如羥乙基或羥丙基纖維素,羧甲基纖維素 等。此種黏度構成劑之用量自約〇 〇1至4 〇重量%。本發明 亦可包含視需要之緩和劑。 標的溶液較好包含至少一種抗微生物劑。本文所用之抗 微生物劑疋義爲非氧化有機藥品,其可經由與微有機體之 化學或物理化學地相互作用而推衍其抗微生物活性。較佳 之抗微生物爲四級銨化合物及雙胍。 ^_____________- 14 * 本紙張尺度適用令國國家榡準(CNS ) Α4規格(2丨〇><297公釐) ----^-----=丨裝---^----1訂------球 - * · - * (请先閲讀背面之注意事項再填寫本頁) 455628 A7 B7 經濟部中央標準局員工消費合作社印策 五、發明説明(12 ) 四級録化合物之代表性實例爲由南化笮烷銨所構成之组 合物或例如氣化正烷基二甲基苄銨之平衡混合物^其他實 例包含用於眼科用途之聚合四級銨鹽,如聚[(二甲基亞 胺)·2-丁烯-1,4-二基氣],[4-叁(2_羥乙基)氨]-2-丁烯基 -w-[舂(2-羥乙基)氨]二氣化物(化學註册號75345_27_6), 通常以聚四級銨1 (p〇lyquaternium 1)®購自ΟΝγχ公司。 代表性之雙弧類爲雙(雙胍類),如補體啶(alexidine)或氣 己症(chlorhexidine)或其鹽,及聚合雙胍類如聚合六亞甲基 雙胍(PHMB)。 以聚合六亞甲基雙胍類(購自威明頓DE之Zeneca),其聚 合物及水可溶之鹽類最佳。通常六亞甲基雙胍聚合物(又稱 爲聚胺丙基雙胍(PAPB)具有達約100 000之分子量。此種化 合物爲已知JL揭示於USP 4,758,595,其揭示併於本文供參 考。 消毒量之抗微生物劑爲至少部份降低所用配方中微機體 敏殖之量。較好,消毒量爲可於4小時内降低2個對數級數 之微生物累積且更好於1小時内降低i個對數級數之量。最 好消毒量爲當使用於所推薦之浸泡時間之保養時可消除隱 形眼鏡上微生物累積之量(FDA化學消毒效率測試-1985年7 月隱形眼鏡溶液草擬指引)。一般,此種藥劑之存在濃度自 約0.00001至約0.5%(w/v),且更好自約〇 00003至约〇 5% (v//v)。 第二種消毒殺菌劑可使用作爲溶液保存劑,但亦具有增 強、補充或擴大其他殺菌劑之抗菌活性菌譜。此包含抗微 -15- (請先閏讀背面之注意事項再填寫本頁) οδ 2 8 Α7 Β7 經濟部中央標準局員工消費合作杜印製 16- 五、發明説明(13 生劑量之可相溶於溶液中且不會沉澱之殺菌劑,濃度自約 0.00001至約0.5重量%且更好自約0 0001至約〇^重量%。適 宜之互補殺菌劑包含(但不限於)硫柳汞或其他苯基汞鹽, 山梨酸,烷基三乙醇胺及其混合物。 本發明组合物中所用殺菌劑之酸加成鹽可衍生自無機或 有機酸。大部份情況下,較好爲衍生自易溶於水且可提供 適於人體使用之陰離子(例如醫藥可接受性陰離子)之酸之 鹽。此種酸之實例爲氫氣酸、氫溴酸、磷酸、硫酸、乙 酸、D-葡糖酸、2-吡咯烷-5-羧酸,甲烷磺酸、碳酸、乳 酸及穀胺酸。以氫氣酸較佳。 本應用中,本發明溶液中殺菌劑或其他成份之量表示在 製成溶液時調配並導入溶液中之量。 本發明溶液可調配於特定之隱形眼鏡保養產品中,如逢 潤溶液、漫泡溶液 '清洗及調節溶液,及功能型鏡片保養 溶液等,及其混合物。 較好本發明調配成”多功能溶液",意指可用以清洗、化 學消毒、貯存及沖洗隱形眼鏡之溶液。此溶液可爲多功能 溶液系統”或"多功能溶液包裝"之一部份。使用多功能溶 液、系統或包装之程序表示爲”多功能消毒方法"。多功能 :谷液並未排除某些配戴者例如對化學消毒劑或其化學藥劑 特別敏感之配戴者可以其他溶液例如在置入眼中之前以無 菌食鹽溶液沖洗鏡片之可能性。,,多功能溶液"一詞亦未排 除使用非每日使用之定期洗潔劑或供移除蛋白質之補充清 潔劑例如一般爲每週使用之酵素清潔劑之可能性。,,清洗” 本紙献度制巾關家標準(CNS ) Α4· (21GX297公趁) ------^----批衣---_---^—ΐτ . , . {請先閱讀背面之注意事項再填寫本頁) 455628 A7 _______B7 五、發明説明(14 ) ' —詞意指溶液含有足以使緊密留持於鏡片之沉積物及隱形 眼鏡片表面上之其他污染物鬆散並移除之濃度之一或多種 清洗劑,特別是當與手洗(例如以溶液輕擦鏡片)或與可揽 動洛液與鏡片接觸之輔助裝置(如機械清洗助器)連用時。 含界面活性劑之溶液之臨界微胞濃度爲評估其清洗效率之 一種方法。 多功能溶液之黏度少於75 cps,較好爲1至50 cps,且更 好1至25 cps,且於總組合物中較好爲至少95%重量容積之 水。 如所述,隱形眼鏡可藉使鏡片與標的水溶液接觸而清 洗。雖然此可藉由使隱形眼鏡簡單地浸泡於溶液中而達 成’但若先使數滴溶液滴於鏡片兩侧並擦洗鏡片一片時間 例如約20秒,則可達更大之清洗效果。接著鏡片可浸泡於 數毫升之標的溶液中,較好使鏡片浸於溶液中至少4小 時。再者’在擦洗步驟後及在浸於溶液中之後,鏡片較好 再以新鮮溶液沖洗。若標的溶液包含抗微生物劑,則標的 溶液不僅可清洗鏡片亦可消毒。但需了解亦可使用其他之" 非化學”消毒方式,如加熱消毒。 經濟部中央標準局員工消費合作社印製 雖然通常並非必要,但亦可併用酵素清潔劑及標的溶液 來處理隱形眼鏡,特別是對易產生大量蛋白質沉積之病 患。若使用酵素片則可使酵素片―直接置於標的溶液中,其 方式類似於USP 5,096,607所述者。 本發明方法之第一具體例中,該方法包括以含有〇. 〇〇5至 1.0重量%含1至12個、較好1至10個碳原子之至少一種膦 _____ -17- 说尺度適财關家鮮(CNS )从胁(21()><297公董)—---- 經濟部中央標準局員工消費合作社印^ 56 2 8 A7 -------B7 五、發明説明(15 ) ' -- 酸或其生理可相纟鹽之水溶液清洗隱形眼鏡。$原子可呈 九取代或未取代分枝或未分枝脂族、環狀脂族或芳香基或 其组合t狀態。膦酸化合物例如上述式(〗)者’較好爲上述 式(II)者’最好爲上述式(m)者,較好膦酸化合物具有可呈 鹽態之1或2個膦酸基。 不希望受理論限制,本化合物中之膦酸基相信可附接至 蛋白#分子並使其自隱形眼鏡材料上鬆脱,該附接作用可 經由或不經由與鄰近存在之鈣或其他離子之中間相互作 用。 較好,本方法包括以本發明之多功能溶液擦洗隱形眼 鏡’接著浸泡於該溶液中共爲丨〇分鐘至4小時之時間,之 後直接將鏡片配戴於眼中。”直接配戴,,意指在將隱形眼鏡 置入或配戴於眼中之前,溶液未經稀釋或未以不同隱形眼 鏡溶液沖洗鏡片。 本發明方法之又一具體例中’所申請之溶液可用以洗清 預計配戴不超過約3個月或預計配戴不超過约3〇天、或預 計配戴不超過約2週之長戴型隱形眼鏡(FRL)。較好,隱形 眼鏡是由包括約00至5莫耳%衍生自曱基丙烯酸(MAA)之重 複早元、10至99莫耳%衍生自甲基丙締酸輕乙醋之重複單 元及約0_5至5莫耳%交聯重複單元之聚合物所製得,交聯 重複單元可衍生自例如二甲基丙烯酸乙二醇酯、二乙烯基 苯、及三甲基丙稀酸三甲基两醋等單體。 在隱形眼鏡取出眼晴時,可分別或補充漫潰該隱形限鏡 於本發明之隱形眼鏡溶液中,且可藉施用該溶液作爲眼滴 -18 · 本紙張尺度適用中國國家標準·(CNS ) ΑΊ規格(210X297公釐} (碕先閱讀背面之注意事項再填寫本頁) 裝 訂 '5 2 8 A7 B7 五、發明説明(16 ) 劑而進一步避免蛋白質蓄積於親水性隱形眼鏡上。·因而, 包括所清化合物之眼科安全溶液可包裝於適合以眼滴劑施 用於眼中之容器中。 以下提供數個實例以説明本發明,該等實例僅用以説明 本發明而非用以限制其範圍。 實例1 標的溶液之較佳調配實例示於下表I。於玻璃燒杯中稱取 所需量之1-羥乙又-1,1-二膦酸四鈉鹽(亦表示爲羥乙二膦 酸四鈉鹽,以DeQuest® 2016購自孟山多公司(聖路易士, MO ),接著以ReNu®多功能溶液調整溶液至總體積而製備 此溶液。所得溶液之pH介於約7.1至7.3之間(若需要,可使 用適宜量之氫氣酸或氣氧化納調整溶液之pH,如表I所 示)。終產物具有下表I所示之組成。 -----^---^----^---:---~lir (請先閲讀背面之注意事項再填寫本頁) 經濟部争央標準局員工消費合作杜印裝 表1 構成 %重量容積 聚六亞甲基雙胍HC1(以20% w/w溶液以 Cosmocil CQ商標購自ICI化學公司 0.00047 硼酸 0.64 硼酸鈉 0.12 乙二胺四乙酸二鈉 0.11 氣化鈉 0.49 普羅胺(Tetronic® 1107購自BASF公司) 1.00 羥乙二膦酸四鈉鹽(以30%(w/w)溶液以 DeQuest® 2016商標購自孟山多公司) 0.10 鹽酸,1N 若需要供調節pH 經氧化納,1N 若需要供調節pH 純水 餘量至100 -19- 本紙張尺度適用中國國家橾隼(CMS ) A4規格(210X25»7公釐) 45 56 2 8 a7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明(17 ) 實例2 爲了進一步説明本發明,以蛋白質沉積物包覆數種軟式 水凝膠隱形眼鏡(FDA,III類,bufilcon A,含水量45%之隱 形眼鏡),接著以數種測試溶液之一處理(如上表I所示,但 包含各種量之DeQuest® 2016化合物)。該等隱形眼鏡接著 與以ReNu® MSP及ReNu®單步驟酵素片所構成之對照溶液 處理之隱形眼鏡比較s 以如下之活體外蛋白質沉積程序處理隱形眼鏡。製備電 解質水溶液,該溶液係由約0.70%氣化鈉、0.17%氯化鉀、 0.22%碳酸氫鈉及0.0005%氣化鈣二水合物所組成。藉添加 氣化物及碳酸鹽至約90%總容積之所需蒸餾水中,接著充 分混合溶液而製備電解質溶液。測量pH JL若需要則以1N HC1或IN NaOH調至7.2 ± 0.1。溶液滲透壓介於280至320 mOsm/kg之間。接著於電解質溶液中添加大約量之蛋白質 溶菌晦使溶液之溶菌酶濃度爲0.10%。所得溶液在適度速度 下混合約3 0分鐘,測量pH(若需要則以IN HC1或IN NaOH 調至7.2 ± 0.1)。亦製備包括約0.85%硼酸、0.09%硼酸鈉及 0.45%氯化鈉之硼酸鹽緩衝食鹽溶液,測量pH(及若需要則 以IN HC1或IN NaOH調至7.2± 0.1)。溶液滲透壓介於280至 320 mOsm/kg之間。 藉由將各隱形眼鏡置於玻璃小-瓶中接著將鏡片浸泡於約5 毫升電解質(含蛋白質)溶液中而使蛋白質沉積物沉積在數 種軟式水凝膠鏡片上。接著封住小瓶並在約8 0 °C熱水浴中 在40 rpms搖晃約20分鐘,隨後使鏡片冷卻至常溫,接著以 -20- 本紙張尺度適用中國國家標率(CN’S > A4規格(210X297公釐) I ~I fc II . I ΊI I ϋ ^ • ·- . (讀先閱讀背面之注意事項再填寫本頁) a b b6 2 8 經濟部中央插準局員工消費合作社印裝 A7 五、發明説明(18 ) — ;- 棚酸鹽緩衝食鹽溶液溫和輕擦洗鏡片以移除任何鬆脱之結 合蛋白質。 、、行蛋白處况積後,以標的溶液或對照·组溶液處理 鏡片’“標的溶液之處理係將數滴測試溶液滴於鏡片兩侧 上’接著擦洗鏡片約2G秒,接著以測試溶液沖洗鏡片並浸 泡於β 5毫升測試落液中4小時,接著鏡片以爛酸鹽緩衝食 鹽使沖洗。對照組溶液之處理係將數滴ReNu® MPS滴於鏡 片兩側接著擦洗鏡片約2 0秒,接著鏡片以新鮮ReNu® MPS;中洗並浸泡於含有一片尺⑽⑨酵素片之约ι〇毫升⑧ MPS中约4小時。隨後以新鮮ReNu® Mps擦洗及沖洗鏡片, 最後以硼酸鹽缓衝食鹽液沖洗。 接續上述處理,使用顯微鏡顯像分析評估鏡片以測定處 理後移除之蛋白質量。顯微鏡顯像分析係對鏡片進行數位 照像並以灰級顯像分析分析表面碎片。此程序包含將各鏡 片置於具有”暗域"背景之顯微鏡下且隨後使之射光通過鏡 片,鏡片上之表面碎片會使光散射並出現比隱形眼鏡乾淨 表面更凴I區域。得到發光鏡片之數位照相並使用}^1{1顯 像V,1.46软體(國立保健協會)基於其光強度而計算/分離像 素。使用0-255之灰級定量覆蓋鏡片之圓形圖中9〇824像素 之値。0値定義爲"白色”而255値定義爲"黑色,,。(由於沉 積物散射光’因此較亮之値表示_愈不清潔之表面)。在各组 (各爲〗0個鏡片)處理前後’記錄該等値之平均(平均密 度)’計算前後之百分比差。像素密度百分比改變愈高,蛋 白質移除愈妤。比較以測試溶液處理之鏡片密度値與以正 _______-21- 本紙張尺度適用中國國家標孪(CNS )以規格< 2丨〇X297公釐一 ------- (讀先聞讀背面之注意事項再填寫本頁}z— P—OH \ 〇H / / n (I) where Z is a linking group having a valence equal to n, where n is 1 to 6, preferably J to 3, and preferably Z contains 1 to 12 carbon atoms And more preferably 1 to 10 carbon atoms. The 2 group includes a substituted or unsubstituted saturated hydrocarbon group or an amine-containing group, and the amine-containing group is a saturated group in which the Angstrom atom is inserted by at least one nitrogen atom, preferably 1 to 3 nitrogen atoms to form a secondary or tertiary amine. The hydrocarbon group a when 2 is an amine-containing group including one or more secondary or tertiary amines, and the number of carbon atoms in Z is at least n + 1. Hydrocarbyl means "branched, unbranched, non-cyclic or cyclic moiety consisting of carbon and hydrogen atoms, substituted or unsubstituted" means unsubstituted or via a molybdenum, molybdenum, amine, or thiol group , Alkylcarboxy, alkoxycarbonyl, or substituted or unsubstituted phenyl, wherein the substituent on the phenyl can be a pixel, a hydroxyl, an amino, a carboxyl, an alkylcarbonyl, or an alkyl group, wherein the alkyl or alkyl group Oxygen contains from 4 to 4 carbon atoms. The preferred element is gas, and the preferred substituents are amine, hydroxyl, and substituted or unsubstituted phenyl. Accordingly, suitable Z groups include substituted or unsubstituted forks Alkyl, substituted or unsubstituted alkylene, aminotri (alkylene) having at least η + 1 carbon atom, aminodi (alkylene) having at least η + 1 carbon atom, alkylene Diamine tetra (alkylene) or dialkylene triamine penta (alkylene), in which each alkylene group is connected to a phosphonic acid group. Preferably, all alkylene groups each contain from 4 to 4 Carbon atoms. Examples of compounds in which the Z group is amine tri (alkylene) include amine tri (ethyl-8- _____________ This paper size 逋Use China National Standard (CNS) Α4 specification (2 丨 0 > < 297 mm) (read the notes on the back of the book before filling out this page)-order the Ministry of Economic Affairs Central Standards Bureau employee consumption cooperation Du 455628 A7 B7 Printed by the Shellfish Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs 5. Description of the invention (6) Phosphonic acid 'amino tris (isopropylidene phosphonic acid), amino di (methylene phosphonic acid) mono (isopropylidene phosphine) Acid) 'and amine mono (fluorenylphosphonic acid) bis (ethylidenephosphonic acid). Compounds in which the Z group is a substituted or unsubstituted alkylidene group Examples include methylenedipic acid' ethylidene monoscale Acid '1- # to propylidene dilinoleic acid. Examples of compounds where the Z group is butanediamine tetra (alkylene) or dialkylene triamine penta (alkylene) include hexamethylene diamine tetra (Methylenephosphonic acid) and diethylenetriaminepenta (methylenephosphonic acid). The compounds of the present invention are commercially available or can be prepared by methods known in the art, including the method disclosed in USP 3,671,644. Halo substitution The phosphonic acid compounds can be prepared from the corresponding hydroxyl substituted phosphonic acid compounds using, for example, PCI3 or PBr2. The solution of the present invention is physiologically compatible. In particular, the solution needs to be "ophthalmologically safe" for contact lenses, meaning that contact lenses treated with this solution are usually uncleaned. It is suitable and safe when placed directly on the eyes, that is, this solution is safe and comfortable when contacting the contact lenses wetted with this solution with the eyes every day. Ophthalmically safe solutions are compatible with the isotonicity of the eyes and pH 'JL includes substances and amounts that are non-cytotoxin according to ISO standards and US. FDA (Food and Drug Administration) regulations. This solution needs to be sterile and free of microbial contamination before release, and statistical evidence is required until this month The necessary degree of the product. The aqueous solution of the present invention preferably includes a phosphonic acid or a physiologically compatible salt thereof within the range of the formula (I) and represented by the following formula (IΪ), -9- --------- ^ --- 1 ---— 1T (please read the note ^^ on the back to save this page) A7 OH ί r——? OH c II ο (Π) 455628 ________ B7 V. Description of the invention (7) X2 (Bu b X '~ ^ CH2) a ~' C— (CH2) where a, b 'c and d are each selected from 0 to 4 An integer, preferably b or 1; X1 is a phosphonic acid group (that is, P (〇H) 2〇) 'hydroxyl (0H), amine (Nh2) or hydrogen (H); and X2 and X3 are each selected from _ prime A group consisting of hydroxy, amine, carboxy 'alkylcarbonyl, alkoxycarbonyl or substituted or unsubstituted phenyl, and methyl. Examples of substituents on phenyl are halogen, hydroxy, amine, oxo and / or alkyl. It is preferred that the aforementioned alkene group and the ethoxy group contain 1 to 4 carbon atoms, and more preferably contain 1 carbon atom. As mentioned above, the total number of carbon atoms in the formula (II) is preferably 1 to 12, more preferably 1 to 10. Other preferred compounds used in the solution of the present invention include compounds represented by the following formula (III) and their physiologically compatible salts in the range of formula (η): 0Η (_2) b H2〇3P— (CH2) a— C— (CH2) c——P〇3H3 (CH2) d CH3 (HI), where a ′ b, c, and d are each selected from integers 0 to 4 and the total number of atoms in formula (in) It is preferably 1 to 12 ′, more preferably 1 to 10. (In other words, formula (I 工 I) ------------ ^ ------ :: ir (please read the notes on the back before filling in the original)) Staff of the Central Standards Bureau of the Ministry of Economic Affairs Printed by a consumer cooperative ___ '-10- 4 5 562 8 A7 B7 5. In the description of the invention (8), the sum of a + b + c + d is preferably 1 to U, more preferably 2 to 9). Particularly preferred species are those where a, b, c, and d in formula (Π) are all 0, especially the tetrasodium salt of 1-lightethinyl-1,1-diphosphonic acid, also expressed as hydroxyethylenediphosphonic acid Tetrasodium salt 'DeQuest® 2016 sodium phosphonate or phosphonate from Monsanto. Organic phosphonic acids and their salts (collectively referred to as "phosphonic acid compounds" are known to those skilled in the art). This salt is sometimes referred to as a phosphonate. The known uses of this phosphonic acid compound include inhibiting scale formation in cookers. Others Known uses include the stabilization of hydrogen peroxide. For example, US Pat. No. 4,812,173 to Tsao et al. Discloses the use of phosphonic acid compounds for the stabilization of contact lenses. This method requires subsequent neutralization Examples of "oxidative" disinfection methods. An example of oxidative disinfection is the detoxification method using peroxides. This reference does not indicate a general "cleaning" or the removal of proteins from contact lenses. This Other known uses of this phosphonic acid compound include the use as a potent agent in antiseptic compositions containing phenols or quaternary ammonium bactericides. This composition has been found to be applicable to drilling mud compositions, pelletized compositions (Such as teeth cleaning 'hand and hair cleaners) and heavy-duty antiseptic cleaner compositions (such as for professional laundry, laundry fabrics, dairy farming equipment, hospital equipment, etc.) Employees of the Central Standards Bureau of the Ministry of Economic Affairs The cost-effective printed aqueous solution of the target should preferably contain at least 0.003% by weight of the standard phosphonic acid in the total solution, preferably 0.005 to 1.0 ° /% by weight, more preferably 0.01 to 0.25% by weight. The target aqueous solution is also May contain a variety of other ingredients, including (but not limited to): antimicrobials' buffers, chelating and / or sequestering agents, isotonic regulators and surfactants. This solution includes at least one surfactant. Suitable Surfactant can be -11- this paper ^ size is applicable to China National Standard (CNS) A4 specifications (210X297 publicly available 1 " printed by the Consumer Cooperatives of the Central Bureau of Standards, Ministry of Economic Affairs 455628 A7 -------- 51 5 2. Description of the invention (9) Group of anionic or non-ionic, the amount (individual amount or tongue two) can reach 15% by weight of the total composition (solution), preferably up to 5% by weight (the interface with better potential) The active agent is amphoteric or non-ionic interfacial active agent, which can be used to impart cleaning and conditioning properties when used. The surfactant needs to be soluble in contact lens solution but not irritating to the eye tissue. Many non-ionic surfactants include-or multiple With oxygen stretch (-0-R-) repeating single = chain or polymer component 'where ^ 2 to 6 complete atoms. Preferred non-isolated :: surfactants include two or more different oxygen-like alkylene repeating units. Polymer. The proportion of different repeating units determines the HLB of the surfactant. Satisfactory non-ionic surfactants include polyethylene glycol esters of fatty acids, such as sorbitan esters of high carbon alkanes (Cim), and polysorbates. Sugar alcohol esters, polyoxyethylene ethers or polyoxypropylene ethers. Preferred examples include polysorbate 20 (supplied under the trade name Tween® 20), polyoxyethylene (23) lauryl ether (Brije 35), Polyoxyethylene (40) stearate (Myrj®52), polyoxyethylene (25) glyceryl stearate (Atlas® G2612). A poly (oxypropylene) _poly (oxyethylammonium) adduct, in particular at least 40% by weight of the adduct, is a poly (oxyethylene) having a molecular weight of from about 7,500 to 27,000. The non-ionic surfactants, when used at about 5% to 5% by weight, are particularly beneficial for cleaning and adjusting both soft and hard contact lenses. The CTFA Cosmetic Ingredient Dictionary The name used is poloxamine »This surfactant can be registered trademark " Tetronic " commercially available from BASF Wondo Company, Wanda, Michigan. A similar series of surfactants suitable for use in the present invention is Pro Roma (Pol〇xamer) series, which is a poly (oxyethylene) poly-12 supplied under the trademark " Pluronic " (purchased from B ASF)-This paper is applicable to the national standard (CMS) A4 specification (2 丨 0 X 297 mm) ^ ---- ^ -------- ίΐτ ------ t-:-(Please read the notes on the back before filling this page) 455628 Ministry of Economic Affairs A7 printed by Bureau Shelley Consumer Cooperatives _______B7 V. Description of Invention (1〇) (oxypropylene Block polymers. A variety of other ionic and amphoteric and anionic surfactants suitable for use in the present invention can be easily published from "North American Editor, McCutchr Division, MC Publishing Company, McCutchr," of Glen Rock NJ07452 in view of the foregoing description. This and the CTFA International Cosmetic Ingredient Handbook published by the Washington DC, Granulated Products, Toiletries, and Fragrances Association are known ^ The amphoteric surfactants suitable for use in the composition of the present invention include those sold under the trade name " Miranol " Other types of amphoteric surfactants that can be used, such as cocoaamine propyl betaine, are purchased from a variety of sources. The aforementioned surfactants are generally total in the range from 0.0 to 50% by weight (w / v) 'better. .d50 0%, and preferably 〇 丨 to 〖50 / 〇. The pH of this solution needs to be maintained in the range of 5.0 to 8.0, more preferably from about 60 to 8.0, and most preferably from about 6.5 to 7.8, Appropriate buffering agents such as butterfly acid, sodium rotate, potassium citrate, sodium citrate, sodium bicarbonate, RIS and various mixed phosphate buffers (including Na2HP04, NaH2P04 and KH2P04 combination) and mixtures thereof can be added. Borate buffer "Good" especially for enhancing the effect of biguanide. Generally the amount of buffering agent is from about 0.05 to 2.5 weight%, more preferably from 0.01 to 1.5%. The disinfection / preservation solution of the present invention contains borate or Mixed phosphate buffering agent ', which contains one or more boric acid' sodium borate 'tetraborate clock, potassium metaborate, or mixtures thereof. In addition to the buffering agent, in some cases, a sequestering agent may be included in the solution. It is preferable to surround metal ions, otherwise, it will react with the lens and / or protein deposits and collect on the lens. Dextral ethylenediaminetetraacetic acid (EDTA) and its salt (disodium) are the preferred examples. The amount of addition is usually from about 0. 〇ι 至 〇3 重量 %. Other suitable sequestrants include gluconic acid and citric acid 'tartaric acid ______ ^ 13- This paper is manufactured by Siljia County (CNS) 44th position (210X297 mm) ~~-(Please read the notes on the back first (Fill in this page again). Binding A7 B7 made by employees of the Central Standards Bureau, Ministry of Economic Affairs, Consumer Cooperatives. 5. Description of the invention ...) and its salts, such as sodium salt. Typically, the aqueous solution of the present invention used to treat contact lenses is also isotonicized to about the osmotic pressure of normal tears, which is equal to 0.9% sodium vaporized solution or 2.5 /. Glycerin drops. This solution can be made isotonic virtually by using physiological saline alone or in combination. Otherwise, if it is simply blended with sterile water, the contact lenses will become hypotonic or hypertonic and lose their required optical parameters. In contrast, excess salt solution can cause the formation of hypertonic solutions, which can cause stinging and eye irritation. Examples of suitable tonicity modifiers include (but are not limited to): sodium and potassium chloride, dextrose, glycerol, calcium and magnesium. These pharmaceuticals are generally used in individual amounts ranging from about 0.001 to 2.5% (w / v) and preferably from about 0.2 to 1.5% (w / v). The preferred isotonicity is used in an amount that provides a final osmotic pressure of between 200 and 450 mOsm / kg and more preferably between about 250 and 350 mOsm / kg and most preferably between about 280 and 320 mOsm / kg between. Yes, it is desirable to include a water-soluble viscosity-constituting agent in the solution of the present invention. Due to its soothing effect, the viscosity-constituting agent has a tendency to improve the comfort of the wearer, and the film on the surface of the lens cushions the impact on the eyes. Such water-soluble constituents include cellulose polymers such as hydroxyethyl or hydroxypropyl cellulose, carboxymethyl cellulose and the like. Such a viscosity-constituting agent is used in an amount of from about 0.01 to 40% by weight. The present invention may also contain a moderator as needed. The target solution preferably contains at least one antimicrobial agent. As used herein, an antimicrobial agent means a non-oxidizing organic drug that can derive its antimicrobial activity through chemical or physicochemical interactions with microorganisms. Preferred antimicrobials are quaternary ammonium compounds and biguanides. ^ _____________- 14 * The size of this paper is applicable to the national standard (CNS) Α4 specification (2 丨 〇 > < 297 mm) ---- ^ ----- = 丨 installed --- ^- --1 Order ------ Ball-* ·-* (Please read the notes on the back before filling out this page) 455628 A7 B7 Imprint by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention (12) IV Representative examples of graded compounds are compositions composed of sulfonium ammonium ammonium or a balanced mixture such as vaporized n-alkyldimethylbenzyl ammonium ^ Other examples include polymeric quaternary ammonium salts for ophthalmic use, such as Poly [(dimethylimine) · 2-butene-1,4-diyl], [4-tris (2-hydroxyethyl) amino] -2-butenyl-w- [舂 (2 -Hydroxyethyl) ammonia] digas (chemical registration number 75345_27_6), which is usually purchased from ONYX Corporation as polyquaternium 1 (Polyquaternium 1) ®. Representative double arcs are big (biguanides), such as alexidine or chlorhexidine or their salts, and polymeric biguanides such as polymerized hexamethylene biguanide (PHMB). To polymerize hexamethylene biguanides (Zeneca from Wilmington DE), the polymers and water-soluble salts are the best. Generally hexamethylene biguanide polymers (also known as polyaminopropyl biguanide (PAPB) have molecular weights up to about 100,000. Such compounds are known as JL disclosed in USP 4,758,595, which is disclosed and incorporated herein by reference. Disinfection Amount The antimicrobial agent is to at least partially reduce the amount of micro organisms in the formula used. Preferably, the disinfection amount is to reduce the accumulation of microorganisms by 2 logarithmic stages within 4 hours and better to reduce i logarithms within 1 hour. The number of levels. The best disinfection amount is the amount that can eliminate the accumulation of microorganisms on contact lenses when used in the maintenance recommended for the immersion time (FDA chemical disinfection efficiency test-July 1985 draft guidelines for contact lens solutions). Generally, Such agents are present at a concentration of from about 0.00001 to about 0.5% (w / v), and more preferably from about 0.0003 to about 05% (v // v). A second disinfectant can be used as a solution preservative , But also has the antibacterial active bacteria spectrum that enhances, supplements or expands other fungicides. This contains anti-micro-15- (please read the precautions on the back before filling this page) οδ 2 8 Α7 Β7 Staff of the Central Standards Bureau of the Ministry of Economic Affairs Consumption Cooperation Du Printing 16- 5 、 Explanation of the invention (13 raw doses of biocides that are miscible in solution and will not precipitate, the concentration is from about 0.00001 to about 0.5% by weight and more preferably from about 0 0001 to about 0 ^% by weight. Suitable complementary bactericides Contains (but is not limited to) thimerosal or other phenylmercury salts, sorbic acid, alkyltriethanolamine, and mixtures thereof. The acid addition salts of the bactericides used in the compositions of the present invention can be derived from inorganic or organic acids. Most cases It is preferably a salt derived from an acid that is easily soluble in water and can provide an anion suitable for human use (such as a pharmaceutically acceptable anion). Examples of such acids are hydrogen acid, hydrobromic acid, phosphoric acid, sulfuric acid, Acetic acid, D-gluconic acid, 2-pyrrolidine-5-carboxylic acid, methanesulfonic acid, carbonic acid, lactic acid, and glutamic acid. Hydrogen acid is preferred. In this application, the fungicide or other ingredients in the solution of the present invention Amount refers to the amount formulated and introduced into the solution when it is made into a solution. The solution of the present invention can be formulated into specific contact lens maintenance products, such as Fengrun solution, diffused bubble solution 'cleaning and conditioning solution, and functional lens maintenance solution, etc. , And mixed The invention is preferably formulated into a "multifunctional solution", which means a solution that can be used to clean, chemically disinfect, store and rinse contact lenses. This solution can be a multifunctional solution system "or" multifunctional solution packaging " Part of the procedure. The use of a multi-functional solution, system or packaging is expressed as "multi-functional disinfection method". Multi-functional: Cereal does not exclude certain wearers such as being particularly sensitive to chemical disinfectants or their chemicals The wearer can use other solutions such as the possibility of rinsing the lenses with a sterile salt solution before placing it in the eyes. The multifunctional solution does not exclude the use of regular detergents for daily use or for protein removal The possibility of supplementary cleansers such as enzyme cleansers that are generally used weekly. ,, cleaning "This paper offers the standard of household towel making (CNS) Α4 · (21GX297) while taking ------ ^ ---- batch clothes ---_--- ^-ΐτ.,. {Please Read the precautions on the back before filling out this page) 455628 A7 _______B7 V. Description of the invention (14) '— The word means that the solution contains enough to loosen the deposits that are tightly held on the lens and other contaminants on the surface of the contact lens. One or more cleaning agents to be removed, especially when used in conjunction with hand-washing (for example, gently rubbing the lens with a solution) or with auxiliary devices (such as mechanical cleaning aids) that come into contact with the lens fluid. The critical cell concentration of the solution of the agent is a method to evaluate its cleaning efficiency. The viscosity of the multifunctional solution is less than 75 cps, preferably 1 to 50 cps, and more preferably 1 to 25 cps, and more in the total composition. It is preferably at least 95% by weight of water. As stated, contact lenses can be cleaned by contacting the lens with the target aqueous solution. Although this can be achieved by simply immersing the contact lens in the solution ', if a few drops are made first Solution drips on both sides of the lens and scrubs the lens for a period of time, such as about 20 seconds A greater cleaning effect can be achieved. Then the lens can be immersed in a few milliliters of the standard solution, preferably the lens is immersed in the solution for at least 4 hours. Furthermore, after the scrubbing step and after immersed in the solution, the lens is more Rinse with a fresh solution. If the target solution contains an antimicrobial agent, the target solution can not only clean the lenses but also sterilize. However, it should be understood that other "non-chemical" disinfection methods, such as heat sterilization, can also be used. Printed by the Consumer Standards Cooperative of the Central Bureau of Standards of the Ministry of Economics Although it is usually not necessary, it is also possible to use a combination of enzyme cleaners and target solutions to treat contact lenses, especially for patients who are prone to large amounts of protein deposits. The use of enzyme tablets allows the enzyme tablets to be placed directly in the target solution in a manner similar to that described in USP 5,096,607. In a first specific example of the method of the present invention, the method includes at least one phosphine containing 1 to 12, preferably 1 to 10 carbon atoms in an amount of 0.05 to 1.0% by weight. Caiguan Jiaxian (CNS) Congxiu (21 () > < 297 public directors) ------ printed by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs ^ 56 2 8 A7 ------- B7 V. Description of the invention (15) '-Cleaning contact lenses with an aqueous solution of an acid or a physiologically compatible salt thereof. The $ atom may be in the t-state of a nine-substituted or unsubstituted branched or unbranched aliphatic, cyclic aliphatic or aromatic group, or a combination thereof. The phosphonic acid compound is preferably one of the above formula (), preferably the one of the formula (II), and more preferably the formula (m). The phosphonic acid compound preferably has one or two phosphonic acid groups in a salt state. Without wishing to be bound by theory, the phosphonic acid group in this compound is believed to attach to the protein # molecule and release it from the contact lens material, and this attachment effect may or may not be caused by the presence of calcium or other ions in the vicinity. Interaction. Preferably, the method includes scrubbing the contact lens with the multifunctional solution of the present invention, and then immersing in the solution for a total of 10 minutes to 4 hours, and then directly wearing the lens in the eye. "Direct wearing" means that the solution is not diluted or the lens is not rinsed with a different contact lens solution before the contact lens is placed in or worn in the eye. In another embodiment of the method of the present invention, 'the applied solution is available The long-wearing contact lenses (FRL), which are expected to be worn for no more than about 3 months or for less than about 30 days, or for not more than about 2 weeks, are washed out. Preferably, contact lenses are composed of About 00 to 5 mol% of repeat units derived from fluorenyl acrylic acid (MAA), 10 to 99 mol% of repeat units derived from methyl ethyl methacrylate and about 0 to 5 to 5 mol% of cross-linked repeats It is made from a polymer of units, and the cross-linked repeating unit can be derived from monomers such as ethylene glycol dimethacrylate, divinylbenzene, and trimethyldiacetic acid. When the eyes are clear, the contact limit lens can be diffused separately or supplemented in the contact lens solution of the present invention, and the solution can be used as the eye drop -18 · This paper size applies the Chinese National Standard (CNS) ΑΊ size (210X297 Mm} (碕 Read the notes on the back before filling (This page) Binding '5 2 8 A7 B7 V. Description of the invention (16) agent to further avoid protein accumulation on hydrophilic contact lenses. · Therefore, ophthalmologically safe solutions including the clear compounds can be packaged suitable for application in eye drops In the container in the eyes. Several examples are provided below to illustrate the present invention, these examples are only used to illustrate the present invention and are not intended to limit its scope. Example 1 A preferred formulation of the target solution is shown in Table I below. The required amount of tetrasodium salt of 1-hydroxyethyl-1,1-diphosphonic acid (also referred to as tetrasodium salt of hydroxyethylene diphosphonic acid) was weighed in a beaker and was purchased from Monsanto Corporation (St. Louis as DeQuest® 2016). (MO, MO), followed by adjusting the solution to the total volume with ReNu® multifunctional solution. The pH of the resulting solution is between about 7.1 to 7.3 (if necessary, it can be adjusted with an appropriate amount of hydrogen acid or sodium oxide) The pH of the solution is shown in Table I). The final product has the composition shown in Table I below. ----- ^ --- ^ ---- ^ ---:-~ lir (Please read first (Notes on the back, please fill in this page) Polyhexamethylene biguanide HC1 (purchased from ICI Chemicals Cosmocil CQ as a 20% w / w solution. 0.00047 Boric acid 0.64 Sodium borate 0.12 Disodium ethylenediamine tetraacetate 0.11 Sodium gasification 0.49 Promine (Tetronic® 1107 purchased from BASF Company) 1.00 Tetrasodium salt of hydroxyethylene diphosphonic acid (purchased from Monsanto as a 30% (w / w) solution under the DeQuest® 2016 trademark) 0.10 Hydrochloric acid, 1N If needed for pH adjustment Sodium oxide, 1N If required For adjusting the pH of pure water to 100 -19- This paper size is applicable to China National Standard (CMS) A4 (210X25 »7mm) 45 56 2 8 a7 B7 Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs Description of the invention (17) Example 2 In order to further illustrate the present invention, several soft hydrogel contact lenses (FDA, class III, bufilcon A, 45% water contact lenses) were coated with protein deposits, followed by several tests Treatment with one of the solutions (as shown in Table I above, but containing various amounts of the DeQuest® 2016 compound). These contact lenses were then compared with contact lenses treated with a control solution consisting of ReNu® MSP and ReNu® single-step enzyme tablets. Contact lenses were treated with the following in vitro protein deposition procedure. An electrolytic electrolyte solution was prepared, which was composed of about 0.70% sodium gaseous, 0.17% potassium chloride, 0.22% sodium bicarbonate, and 0.0005% calcium carbonate dihydrate. An electrolyte solution is prepared by adding vapors and carbonates to about 90% of the total volume of the desired distilled water, followed by sufficient mixing of the solutions. Measure pH JL if necessary. Adjust to 7.2 ± 0.1 with 1N HC1 or IN NaOH. The osmotic pressure of the solution is between 280 and 320 mOsm / kg. Next, an approximate amount of protein was added to the electrolyte solution, so that the lysozyme concentration of the solution was 0.10%. The resulting solution was mixed at a moderate speed for about 30 minutes and the pH was measured (adjusted to IN HC1 or IN NaOH to 7.2 ± 0.1 if necessary). A borate buffered common salt solution including about 0.85% boric acid, 0.09% sodium borate, and 0.45% sodium chloride was also prepared, and the pH was measured (and adjusted to IN HC1 or IN NaOH to 7.2 ± 0.1 if necessary). The osmotic pressure of the solution is between 280 and 320 mOsm / kg. Protein deposits were deposited on several soft hydrogel lenses by placing each contact lens in a glass vial and then immersing the lens in about 5 ml of an electrolyte (containing protein) solution. Then, the vial was sealed and shaken at 40 rpms in a hot water bath at about 80 ° C for about 20 minutes, and then the lens was cooled to normal temperature, and then the Chinese national standard (CN'S > A4 specification (CN4) ( 210X297 mm) I ~ I fc II. I ΊI I ϋ ^ • ·-. (Read the precautions on the back before filling in this page) ab b6 2 8 Printed by the Consumer Cooperatives of the Central Interpretation Bureau of the Ministry of Economic Affairs A7 Fifth, Description of the invention (18)-;--The lens buffered saline solution gently scrubs the lens to remove any loose binding protein. After the protein is accumulated, the lens is treated with the target solution or control group solution. The treatment of the solution is to drop a few drops of test solution on both sides of the lens', then scrub the lens for about 2G seconds, then rinse the lens with the test solution and soak it in β 5 ml test solution for 4 hours, and then the lens is buffered with salt by rotten salt The treatment of the control solution is to place a few drops of ReNu® MPS on both sides of the lens and then scrub the lens for about 20 seconds. Then, the lens is washed with fresh ReNu® MPS; 〇mL⑧MPS Approximately 4 hours. The lenses are then scrubbed and rinsed with fresh ReNu® Mps, and finally rinsed with borate buffered saline. Following the above treatment, the lenses are evaluated using microscope imaging analysis to determine the amount of protein removed after the treatment. Microscopic imaging analysis This is a digital image of the lens and analysis of surface debris with grayscale analysis. This procedure involves placing each lens under a microscope with a "dark field" background and then passing light through the lens. Surface debris on the lens will Scatter the light and show a larger area than a clean surface of a contact lens. Obtain a digital photo of the luminescent lens and use} ^ 1 {1 Imaging V, 1.46 software (National Health Care Association) to calculate / separate pixels based on their light intensity. Use The gray scale quantitative coverage of 0-255 covers 値 824 pixels in the circle diagram of the lens. 0 値 is defined as " white " and 255 値 is defined as " black, " (due to the scattered light from the deposits, it is brighter. "値" means _the less clean the surface). The percentage difference before and after 'recording the average (average density) of such 値' before and after the treatment of each group (0 lenses each). The higher the percentage change in the density of protein, the more the protein is removed. Compare the density of the lens treated with the test solution to the positive _______- 21- This paper size applies to China National Standards (CNS) with specifications < 2 丨 〇X297 Liyi ------- (Read the notes on the back first and then fill out this page)
56 2 8 A7 B7 五、發明説明(19 ) 面對照组溶液處理之鏡片密度値。由該等數據測定各鏡片 之相對蛋白質移除。評估結果列於表Π,其中相對蛋白質 移除於表II中係表示與對照組溶液相較時像素密度之百分 比變化。 ---------t---^---------^ - . · - · (锖先閲讀背面之注意事項再填寫本I) 經濟部中央標準局負工消費合作社印製 各實施係依據以相同方式處理之1 0個鏡片所收集之數據 所完成。如表II所引之數據顯示,取各濃度之平均,處理 鏡片之標的溶液及方法可提供可·與對照組溶液(包含使用酵 素清洗)相較之蛋白質移除,雖然其在較低濃度活性降低。 除了提供優異清洗外,標的溶液亦提供可與對照组溶液相 較之消毒作用。 -22-56 2 8 A7 B7 V. Description of the invention (19) The density of the lens treated with the solution of the control group is 値. From these data, the relative protein removal of each lens was determined. The evaluation results are listed in Table II, where the relative protein removal in Table II indicates the percentage change in pixel density when compared to the control solution. --------- t --- ^ --------- ^-. ·-(锖 Please read the notes on the back before filling in this I) Cooperative printing is implemented based on data collected from the 10 lenses processed in the same way. As the data cited in Table II shows, taking the average of each concentration, the target solution and method for treating lenses can provide protein removal compared to the control solution (including the use of enzyme cleaning), although its activity at lower concentrations reduce. In addition to providing excellent cleaning, the target solution also provides a disinfecting effect comparable to that of the control group. -twenty two-
表II 實例编號 相對於對照组之像素密度變化% (對照组=100%) 1 (0.01%DeQuest® 2016) 82% 2 (0.01%DeQuest® 2016) 59% 3 (0.01%DeQuest® 2016) 0.0% 4 (0.05%DeQuest® 2016) 83% 5 (0.05%DeQuest® 2016) 76% 6 (0.10%DeQuest® 2016) 76% 7 (0.10%DeQuest® 2016) 91% 8 (0.10%DeQuest® 2016) 133% 9 (0.25%DeQuest® 2016) 79% 10 (0.25%DeQuest® 2016) 167% 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) 經濟部中央標準局員工消費合作社印製 455628 A7 _________B7 五、發明説明(20 ) 實例3 此實例進一步説明本發明,係測試其他之膦酸化合物用 以避免或移除鏡片上蛋白質沉積物之能力。使用實例2所 述之活體外蛋白質沉積程序,使軟式水凝膠鏡片(FDA,ΙΠ 類,bufilccm Α)進行蛋白質沉積,接著以類似於上述表1之 溶液之各種測試溶液處理,但溶液中包含各種量之各種瞬 酸化合物。蛋白質沉積後,以標的溶液或正面對照組(比較 用)溶液處理鏡片,該對照組溶液亦由ReNu® 1^?$與1^1^11® 單步驟酵素片及枯草溶菌素、碳酸鈉、氣化鈉及硼酸所構 成。此處理後’使用顯微鏡顯像分析評估鏡片以測定處理 後蛋白質.移除量。如上所述,顯微鏡顯像分析係對鏡片進 行數位照相並以灰級顯像分析分析表面碎片,其中各鏡片 置於具有"暗區"背景之顯微鏡下並使入射光通過鏡片^得 到發光鏡片之數位顯像且基於其光強度計算/分離像素。以 測試溶液處理之鏡片密度儘與以正面對照組溶液處理之鏡 片比較’評估結果列於表III ’其顯示像素密度之百分比變 化。該表顯示(1)使用含既定膦酸化合物之標的溶液之像素 密度百分比變化,(2)使用比較用酵素溶液之像素密度百分 比變化,及最後一攔,(3)比較(1)至(2)之像素密度之相 對百分比變化。表III中之化合物藉由符合下列兩個標準之 至少一個標準之測試結果而顯現_蛋白質移除活性·( 1 )顯現 約80%或更大之相對百分比變化,及/或(2)顯現以化合物 大於15%之百分比變化。負面對照組(ReNu® MPS溶液)之百 分比變化平均値約爲15%。 23- 本紙張尺度適用中國國家梯準(CNS ) A4規格(210X;297公釐) "--- -----^---^----裝------訂------冰 ' * : / (請先閲讀背面之注意事項再填寫本荑) 4 5 56 2 8 A7Table II% change in pixel density of the example number relative to the control group (control group = 100%) 1 (0.01% DeQuest® 2016) 82% 2 (0.01% DeQuest® 2016) 59% 3 (0.01% DeQuest® 2016) 0.0 % 4 (0.05% DeQuest® 2016) 83% 5 (0.05% DeQuest® 2016) 76% 6 (0.10% DeQuest® 2016) 76% 7 (0.10% DeQuest® 2016) 91% 8 (0.10% DeQuest® 2016) 133 % 9 (0.25% DeQuest® 2016) 79% 10 (0.25% DeQuest® 2016) 167% This paper size applies to China National Standard (CNS) A4 (210 X 297 mm) Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 455628 A7 _________B7 V. Description of the Invention (20) Example 3 This example further illustrates the present invention and tests the ability of other phosphonic acid compounds to avoid or remove protein deposits on lenses. Using the in vitro protein deposition procedure described in Example 2, the soft hydrogel lens (FDA, Class I, bufilccm A) was used for protein deposition, and then treated with various test solutions similar to the solutions in Table 1 above, but the solution contained Various amounts of various instant acid compounds. After the protein is deposited, the lenses are treated with the target solution or the positive control solution (comparative), which is also composed of ReNu® 1 ^? $ And 1 ^ 1 ^ 11® single-step enzyme tablets and subtilisin, sodium carbonate, Composed of vaporized sodium and boric acid. After this treatment ', the lens was evaluated using microscope imaging analysis to determine the amount of protein removed after the treatment. As described above, the microscope imaging analysis system digitally photographs the lenses and analyzes the surface debris with gray-scale imaging analysis, in which each lens is placed under a microscope with a "dark area" background and the incident light passes through the lens to obtain light emission. The lenses are digitally developed and pixels are calculated / separated based on their light intensity. Comparison of the density of lenses treated with the test solution with lenses treated with the front control solution is shown in Table III, which shows the percentage change in pixel density. The table shows (1) the percentage change in pixel density using a target solution containing a given phosphonic acid compound, (2) the percentage change in pixel density using a comparison enzyme solution, and the last stop, (3) comparing (1) to (2 ) Relative percentage change in pixel density. The compounds in Table III are manifested by test results that meet at least one of the following two criteria:-Protein removal activity. (1) exhibit a relative percentage change of approximately 80% or greater, and / or (2) exhibit Compounds vary by more than 15%. The percentage change in the negative control group (ReNu® MPS solution) averaged approximately 15%. 23- The size of this paper is applicable to China National Standard for Ladder (CNS) A4 (210X; 297 mm) " --- ----- ^ --- ^ ---- installation ------ order- ----- Ice '*: / (Please read the notes on the back before filling in this card) 4 5 56 2 8 A7
B 五、發明説明(21 ) 經濟部中央標隼局員工消費合作社印裝 表III 測試 編號 鱗酸化合物 Wt. %(w/v) 化合物 以化合物 之變化% 以酵素 之變化% 化合物對 對照组之 相對變化% 1 1-羥乙又-1,1-二 膦酸四纳鹽 0.075 10 6 167 2 亞甲基二膦酸三 鈉鹽四永合物 0.10 10 6 167 3 2-甲基苄基膦酸 0.10 27 18 150 4 1-羥乙叉-1,1-二 膦酸四納鹽 0.030 8 6 133 5 亞曱基二膦酸三 鈉鹽四水合物 0.01 8 6 133 6 2-胺乙基膦酸 0.10 23 19 121 7 2-胺乙基膦酸· 0.01 23 19 121 8 2-甲基芊基膦酸 0.10 53 58 91 9 1-羥乙叉-1,1-二 膦酸四纳鹽 0.030 30 J J 91 10 1-羥乙叉-1,1-二 膦酸四纳鹽 0.015 5 6 83 11 1-羥乙又-1,1-二 膦酸四納鹽 0.003 27 33 82 12 胺基甲烷膦酸 0.10 26 32 81 13 (4-胺芊基)膦酸 0.10 26 39 67 14 膦醯乙酸 0.01 24 37 65 15 DL-2-胺基-4-膦 醯丁酸 0.10 18 28 64 16 正癸基膦酸 0.10 20 32 63 17 膦醯乙酸 0.10 23 37 62 18 芊基瞵酸 0.10 19 31 61 -24- I-----^----- 裝-------訂------冰 - 4 '' (請先閣讀背面之注意事項再填寫本頁) 本紙悵尺度適用中國國家橾準(CNS ) A4規格(210 X 297公釐) 45562 8 Λ7 B7 五 '發明説明(22 ) 測試 编號 膦酸化合物 Wt_% (w/v) 化合物 以化合物 之變化% 1 *-- 以酵素 之變化% 化合物對 對照組之 相對變化% 19 1-羥乙又-1,1-二膦 酸四納鹽 0.003 20 34 59 20 2-膦硫丙酸 0.10 18 31 58 21 4-膦醯丁酸 —*------_ 0.10 17 31 55 22 六亞曱基二胺四(亞 甲基膦酸)六钟鹽 0.10 ~~' 27 53 51 23 鱗醯丙酸 0.10 14 28 50 24 胺甲烷膦酸 0.10 14 32 44 25 2-膦醯丁酸 ------. 0.10 ~----. 0.10 11 31 35 26 二伸乙三胺五(亞甲 基膦酸)六納鹽 18 53 34 27 亞甲基二膦酸 0.10 10 31 32 28 3-鱗酿丙酸 -----—_ 0.10 —---— 8 28 29 ----—------裝---^----j 訂------咏 (請先閲讀背面之·注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 *表中所有化合物均商業購#,例如化合物…,9, 10,11及19係購自孟山多公司 』(路易士);化合物2,5及 13係構淋B公司(威斯康辛,8,12及24# 特公司(賓西法尼亞Γ;化合物14,17及23係購 自西格瑪化學公司(聖路易士);及化合物2〇,21,25, 27及28係購自橡木研究化學公司(南卡羅那州)。 由表Π!之數據顯示,含膦酸化合物之標的溶液及以其處 -25- 蘇尺度適用中固國家榇準(^Π^72;χ297公疫 455628 A7 B7 五、發明説明(23 理隱形眼鏡之方,法,在至少-個測試分數中,㈣面" 组提供更佳之蛋白質移除。所選擇或較佳之化合物提供^ 與使用酵素清洗劑之正面對照組溶液可相較或甚至更佳之 蛋白質移除。 I---^---^-----装---^---:丨訂------沭 - . ; . (請先閱讀背面之注項再填寫本頁) 經濟部中央標準局員工消費合作社印製 26- 本紙張尺度適用中國國家標準(CNS > A4規格(2IOX297公釐)B. V. Description of the invention (21) Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs. Table III. Test No. Lepidic acid compound Wt.% (W / v). Change in the compound from the compound.% Change in the enzyme. Relative change% 1 1-Hydroxyethylene-1,1-diphosphonic acid tetra nano salt 0.075 10 6 167 2 Methylene diphosphonic acid trisodium salt tetra-permanganate 0.10 10 6 167 3 2-methylbenzylphosphonic acid 0.10 27 18 150 4 1-Hydroxyethylidene-1,1-diphosphonic acid tetra sodium salt 0.030 8 6 133 5 Trimethylene diphosphonic acid trisodium salt tetrahydrate 0.01 8 6 133 6 2-aminoethylphosphonic acid 0.10 23 19 121 7 2-Aminoethylphosphonic acid 0.01 23 19 121 8 2-Methylphosphonophosphonic acid 0.10 53 58 91 9 1-Hydroxyethylidene-1,1-diphosphonic acid tetra nano salt 0.030 30 JJ 91 10 1-Hydroxyethylidene-1,1-bisphosphonic acid tetra sodium salt 0.015 5 6 83 11 1-Hydroxyethylene-1,1-bisphosphonic acid tetra nano salt 0.003 27 33 82 12 Aminomethanephosphonic acid 0.10 26 32 81 13 (4-Aminophosphono) phosphonic acid 0.10 26 39 67 14 Phosphonoacetic acid 0.01 24 37 65 15 DL-2-Amino-4-phosphinophosphonic acid 0.10 18 28 64 16 n-decylphosphonic acid 0.10 20 32 63 17 phosphonium acetic acid 0.10 23 37 62 18 fluorenyl fluorene 0.10 19 31 61 -24- I ----- ^ ----- Loading ------- Order ------ Ice- 4 '' (Please read the precautions on the back before filling (This page) The paper's specifications apply to China National Standards (CNS) A4 (210 X 297 mm) 45562 8 Λ7 B7 Five 'invention description (22) Test number Phosphonic acid compound Wt_% (w / v) Compound to compound % Of change 1 *-Relative change of enzyme% relative change of control group 19 1-Hydroxyethylene-1,1-diphosphonic acid tetra sodium salt 0.003 20 34 59 20 2-Phosphinothiopropionic acid 0.10 18 31 58 21 4-Phosphonobutyric acid — * ------_ 0.10 17 31 55 22 Hexamethylenediamine tetra (methylenephosphonic acid) six bell salt 0.10 ~~ '27 53 51 23 Propanoic acid 0.10 14 28 50 24 Aminomethanephosphonic acid 0.10 14 32 44 25 2-Phosphonic acid butyric acid ------- 0.10 ~ ----. 0.10 11 31 35 26 Diethylene glycol triamine penta (methylene Phosphonic acid) hexananosalt 18 53 34 27 methylene bisphosphonic acid 0.10 10 31 32 28 3-scale brewing propionic acid --------- 0.10 ------ 8 28 29 ------- ----- Equipment --- ^ ---- j Order ------ Yong (please read the precautions on the back before filling in this page) Staff Consumption of Central Bureau of Standards, Ministry of Economic Affairs All compounds in the table printed by the cooperative are commercially available. For example, compounds…, 9, 10, 11 and 19 were purchased from Monsanto Company ”(Louis); Compounds 2, 5 and 13 were manufactured by Company B (Wisconsin) , 8, 12, and 24 # Special company (Pennsylvania Γ; compounds 14, 17 and 23 were purchased from Sigma Chemical Company (St. Louis); and compounds 20, 21, 25, 27 and 28 were purchased from oak Research Chemical Company (South Carolina). According to the data in Table Π !, the target solution containing phosphonic acid compounds and its treatments are applicable to the standard of the National Solid State (^ Π ^ 72; χ297 公 455455628 A7 B7) The method of eyeglasses, in at least one test score, the noodle " group provides better protein removal. The selected or better compound provides ^ compared with or even more than the positive control solution using an enzyme cleaning agent Best protein removal. I --- ^ --- ^ ----- pack --- ^ ---: 丨 order ------ 沭-.;. (Please read the note on the back before (Fill in this page) Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs 26- This paper size applies to Chinese national standards (CNS > A4 size (2IOX297 mm)
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3318397A | 1997-02-06 | 1997-02-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW455628B true TW455628B (en) | 2001-09-21 |
Family
ID=21868980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW086103303A TW455628B (en) | 1997-02-06 | 1997-03-17 | Contact lenses with aqueous solution including phosphonic compounds and cleaning aqueous solution thereof |
Country Status (1)
Country | Link |
---|---|
TW (1) | TW455628B (en) |
-
1997
- 1997-03-17 TW TW086103303A patent/TW455628B/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5858937A (en) | Treatment of contact lenses with aqueous solution including phosphonic compounds | |
EP1140224B1 (en) | Contact lens cleaner comprising biguanide, tyloxapol and poloxamine | |
TW490483B (en) | Method of disinfecting or cleaning and disinfecting a soft contact lens with a multi-purpose solution or effective multi-purpose solution and aqueous solution having a ph from 5 to 8 for treating contact lenses | |
EP1030692B1 (en) | Treatment of contact lenses with aqueous solution comprising an alkali carbonate | |
US6309596B1 (en) | Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by a poloxamine | |
TWI322828B (en) | Use of multifunctional surface active agents to clean contact lenses | |
JP2006506192A (en) | Multi-purpose contact lens care composition containing propylene glycol or glycerin | |
HU228749B1 (en) | Positions and methods for cleaning contact lenses | |
US20100086514A1 (en) | Contact Lens Care Solutions with a Low Molecular Weight Oligomer | |
JP2004538096A (en) | Compositions and methods for inhibiting uptake of biguanide antimicrobial agents by hydrogels | |
US20080218686A1 (en) | Lens care solutions for use with contact lenses or contact lens cases that contain silver | |
US20080197324A1 (en) | Ophthalmic composition containing a polyol-acid copolymer | |
US6514528B1 (en) | Composition and method for inhibiting uptake of biguanide disinfectants by poly(ethylene) | |
TW455628B (en) | Contact lenses with aqueous solution including phosphonic compounds and cleaning aqueous solution thereof | |
JP4271728B2 (en) | Treatment of contact lenses using aqueous solutions containing phosphonic compounds | |
MXPA98006971A (en) | Treatment of contact lenses with aqueous solution that includes composites fosfoni | |
WO2017081613A1 (en) | Composition for treating contact lenses with an aqueous solution resulting in visible protein removal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MK4A | Expiration of patent term of an invention patent |